Robert Matusz, DPM
Podiatrist · Naugatuck, CTNPI 1316931843
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Paratek Pharmaceuticals, Inc. at 35.0% of the total. Reporting peaked in 2019 at $668 and has fallen 59.2% since, to $272 in 2025.
Across 162 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$912
- Smith+Nephew$453
- Amgen$180
- KCI USA, Inc.$153
- Averitas Pharma Inc.$148
- Medtronic$148
- plus $608 from 14 others
What the payments were for
- Food & beverage$2,602100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 92 | $912 |
| Smith+Nephew | 20 | $453 |
| Amgen(2 entities) | 5 | $180 |
| KCI USA, Inc. | 5 | $153 |
| Averitas Pharma Inc. | 5 | $148 |
| Medtronic | 5 | $148 |
| Next Science LLC | 4 | $112 |
| Merck | 5 | $77 |
| Reprise Biomedical, Inc. | 2 | $69 |
| Alfasigma USA, Inc. | 3 | $63 |
| Melinta Therapeutics, LLC | 3 | $57 |
| Convatec Inc. | 2 | $34 |
| GRT US Holding, Inc. | 2 | $33 |
| Organogenesis Inc. | 2 | $33 |
| Bioventus LLC | 2 | $32 |
| Stryker | 1 | $31 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $23 |
| Vertex | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| Terumo Medical Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,602 in reported general payments places this provider in the 80th percentile of 119 podiatrist providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JubliaEfinaconazole | 54 | $45,894 |
| Diclofenac Sodium | 29 | $4,124 |
| Ammonium Lactate | 208 | $3,917 |
| Gabapentin | 201 | $2,825 |
| Pregabalin | 44 | $1,623 |
| Cephalexin | 95 | $1,055 |
| Allopurinol | 82 | $990 |
| Clotrimazole | 64 | $973 |
| Ibuprofen | 110 | $870 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 16 | $839 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 41 | $784 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 143 | $495 |
| Meloxicam | 90 | $340 |
| Terbinafine Hcl | 58 | $291 |
| Tramadol Hcl | 49 | $199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $23 | $45,89454 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 119 podiatrist providers in Connecticut.
Other podiatrist in Naugatuck
- David MaderNaugatuck$1K
- Peter BlumeNew Haven$481K
- Robert DavisBridgeport$427K
- David NovickiMilford$67K
- Shane ReynoldsNorwalk$14K
- Eric LevineNorwich$12K
- Paul BetschartDanbury$10K
- Michael FeinBethel$9K
- Tehreem SajjadNew Britain$9K
- Christopher YardanWallingford$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.